<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82222">
  <stage>Registered</stage>
  <submitdate>18/08/2007</submitdate>
  <approvaldate>24/08/2007</approvaldate>
  <actrnumber>ACTRN12607000431426</actrnumber>
  <trial_identification>
    <studytitle>A Phase 1, open label, repeat-dose, dose escalation study of the safety and tolerability of Staphylococcal protein A in adult patients with chronic Idiopathic Thrombocytopenic Purpura (ITP)</studytitle>
    <scientifictitle>An open label, sequential, dose escalation, repeat-dose study of the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of PRTX-100 in adult patients with chronic Idiopathic Thrombocytopenic Purpura (ITP)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Thrombocytopenic Purpura</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sequential cohorts of patients will receive 4 weekly intravenous doses of PRTX-100: Cohort 1 (0.075 mcg/kg), Cohort 2 (0.15 mcg/kg), Cohort 3 (0.30 mcg/kg).  After a Safety Monitoring Committee reviews safety data through Day 28 for the first 5 patients in a dose group and approves dose escalation, the next dose group will be enrolled and dosed at the next higher dose level.</interventions>
    <comparator>No comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>Days 0, 1,2, 7, 14, 21, 22,23,28,35,49,63,84.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the pharamcokinetics of PRTX-100</outcome>
      <timepoint>During the 1st and 4th dosing of PRTX-100 at the following times: pre-dose, within 5 min post-dose, and at 30, 60 and 180 min post-dose.  Samples also obtained on Days 1, 2, 7, 14, 22, 23, 28 and 35.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Explore immunogenicity of multiple doses of PRTX-100</outcome>
      <timepoint>Days 0 pre-dose, 14, 28, 35, 63 and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate treatment effect on platelet count</outcome>
      <timepoint>Days 28 and 35 after 1st treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Diagnosis of chronic ITP &gt;4 months
 Mean platelet count &lt;50x109/L within 30 days prior to study start for patients not receiving corticosteroids; &lt;90x109/L within 30 days prior to study start for patients receiving stable dose of corticosteroids</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Splenectomy within 45 days of screening
 Clinically significant history or evidence (as determined by the Investigator) of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorders which would increase risk to the patient in this study
 Treatment with rituximab within 6 months prior to screening
 Treatment with cyclophosphamide, vincristine, or any other non-monoclonal antibody treatment for ITP within 3 months prior to screening, with the exception of steroid sparing adjunctive treatment with cyclosporine or azathioprine
 Treatment with intravenous immunoglobulin (IVIG), WinRhoÂ® or other anti-RhD within 30 days prior to screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Three cohort dose escalation</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>21</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protalex, Inc.</primarysponsorname>
    <primarysponsoraddress>New Hope, PA 18938</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protalex, Inc.</fundingname>
      <fundingaddress>New Hope, PA 18938</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Trident Clinical Research Pty Ltd</sponsorname>
      <sponsoraddress>Gordon NSW 2072</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the safety of multiple doses of Staphylococcal protein A (PRTX-100).  Patients may be enrolled into 1 of 3 dose groups.  A Safety Committee will review safety data through Day 28 for the first 5 patients in a dose group.  Only upon the Safety Committee's approval will the next higher dose group be enrolled and dosed.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>31/07/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Freemantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/08/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>30/08/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. George Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>3/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>New ethics address. Please modify.</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate>24/10/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth</ethicname>
      <ethicaddress>New ethics address. Please modify.</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate>3/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Middlemore Hospital</ethicname>
      <ethicaddress>New ethics address. Please modify.</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate>26/10/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edward Bernton, MD</name>
      <address>Protalex, Inc.
145 Union Square
New Hope, PA 18938</address>
      <phone>+1 215-862-9720</phone>
      <fax />
      <email>ebernton@protalex.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anissa Leh, MS</name>
      <address>Protalex, Inc. 145 Union Square, New Hope, PA 18938</address>
      <phone>+1 215 862 9720</phone>
      <fax />
      <email>aleh@protalex.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>